The Clinic Value Of3.0T MRI In The Diagnosis Of Hypertrophic Cardiomyopathy

Objective: To explore the clinical value of3.0T cardiac MRI in the diagnosis ofhypertrophic cardiomyopathy (HCM).Methods: A retrospective analysis of diagnosis of hypertrophic cardiomyopathy in40patients and30normal volunteers with3.0T MRI. Scanning all patients and volunteerswith Cardiovascular Magnetic Resonance(CMR)、 echocardiography andelectrocardiography(ECG). There are12patients who have been found hypoperfusionin endocardial of hypertrophic myocardial segments, then using coronary CTA to checkthem. The interval between the various inspection methods are less than two weeks, andno cardiac events occurred during the interval. Cardiac magnetic resonance imagingexamination including cardiac morphology、 left ventricular function imaging,myocardial perfusion imaging, myocardial viability imaging. Application Argus cardiacfunction software to analysis results and measure the left ventricular ejection fraction(LVEF), which compared with the results of echocardiography. To explore theadvantages of the evaluation of left ventricular function with CMR. Applying thescientific statistical method to compared the differences of ejection fraction betweennon-obstructive hypertrophic cardiomyopath、obstructive hypertrophic cardiomyopathyand normol group, in order to evaluate the heart function of patients with hypertrophiccardiomyopathy. Compare analysis of the hypoperfusion of hypertrophic cardiac withmyocardial perfusion imaging in correlation with the results of coronary CTA. Comparative analysis of myocardial viability scan abnormal enhancement segment withECG abnormalities characteristic.Results: Depending on different parts of hypertrophic cardiomyopathy, HCM accountedfor31cases of septal hypertrophy,5cases of apical hypertrophy,2cases of diffusehypertrophy and2cases of left mid-ventricular hypertrophic obstructivecardiomyopathy. Depending on whether left ventricular outflow tract obstruction existed,there are19cases of obstructive hypertrophic cardiomyopathy and21cases ofnon-obstructive hypertrophic cardiomyopathy.40cases of HCM patients with cardiacmagnetic resonance examination proceeds group mean EF (70.60±9.77)%is higherthan the group mean EF (59.55±4.14)%with echocardiography, and the difference wasstatistically significant (P <0.05). The obstructive HCM patients mean EF(79.93±5.23)%is higher than in the control group mean EF (63.48±8.47)%, and thedifference was statistically significant (P <0.05), but there is no statistically significantbetween the non-obstructive HCM patients mean EF (64.12±8.51)%and the controlgroup mean EF (63.48±8.47)%. The group consisted of12patients with hypertrophiccardiomyopathy following sections endomyocardial hypoperfusion, but coronary CTAimaging results were negative. There are20patients had delayed enhancement ofmyocardial viability imaging, and14patients had ECG abnormalities in this group.Conclusion: Cardiac magnetic resonance imaging techniques can be used as adiagnostic of hypertrophic cardiomyopathy and it can accurately measure cardiacfunction in hypertrophic cardiomyopathy. CMR myocardial perfusion, myocardialviability imaging can assess whether there are microcirculations and myocardial fibrosisexisted in HCM. It has a great significance for the risk assessment of hypertrophiccardiomyopathy、the prevention of fatal arrhythmias and the prevention of sudden death.